MAY 14, 2019 3:20 PM PDT

Common food additive could lead to colorectal cancer

Have you ever heard of E171? Otherwise known as titanium dioxide nanoparticles, E171 is a common additive in foods and medicines and is used as a whitening agent in over 900 different foods, from chewing gum to mayonnaise. New research published in Frontiers in Nutrition investigates the adverse effect that food additive E171 has on gut microbiota, which is thought to be correlated to diseases like inflammatory bowel diseases and colorectal cancer.

Food additive E171 is used as a whitening agent. Photo: Pixabay

The research comes from scientists at the University of Sydney and was conducted on mice, who were given foods with E171. While the presence of the additive was not found to alter the composition of gut microbiota, it did change the bacteria’s activity. One consequence the researchers noticed was the formation of biofilms, or bacteria that stick together, which has been known to be related to colorectal cancer.

"It is well established that dietary composition has an impact on physiology and health, yet the role of food additives is poorly understood," said Associate Professor Wojciech Chrzanowski, co-lead author of the study and a nanotoxicology expert from the University of Sydney's School of Pharmacy and Sydney Nano Institute. "There is increasing evidence that continuous exposure to nanoparticles has an impact on gut microbiota composition, and since gut microbiota is a gate keeper of our health, any changes to its function have an influence on overall health."

"This study presents pivotal evidence that consumption of food containing food additive E171 (titanium dioxide) affects gut microbiota as well as inflammation in the gut, which could lead to diseases such as inflammatory bowel diseases and colorectal cancer," said Chrzanowski.

This isn’t the first strike against E171. The use of titanium dioxide and other nanoparticles has already been linked to rising rates of dementia, auto-immune diseases, cancer metastasis, eczema, asthma, and autism – though the researchers agree that more investigation is needed in order to fully understand its long-term impacts.

Co-lead author Associate Professor Laurence Macia from the University of Sydney said: "Our research showed that titanium dioxide interacts with bacteria in the gut and impairs some of their functions which may result in the development of diseases. We are saying that its consumption should be better regulated by food authorities."

Sources: Science Daily, Frontiers in Nutrition

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
JAN 25, 2020
Drug Discovery & Development
JAN 25, 2020
Possible New Drug Targets for Glioblastoma
Scientists at Karolinska Institutet in Sweden were able to pinpoint 10 tumor-specific potential drug targets for the fatal and incurable brain cancer, glio...
JAN 25, 2020
Genetics & Genomics
JAN 25, 2020
Learning More About Changes in Cancer Cell Identity
Cancer cells can change their identity and can take on new functions and characteristics, which is often rooted in epigenetic alterations....
JAN 25, 2020
Cancer
JAN 25, 2020
Using AI to determine which patients are best suited for immunotherapy
A new study published in the journal Cancer Immunology Research suggests that we can use artificial intelligence to help determine which people with lung c...
JAN 25, 2020
Drug Discovery & Development
JAN 25, 2020
New Drug Combo Reverses Breast Cancer
Researchers from Georgetown University have found that combining a drug used for epilepsy, bipolar disorder, and migraines with a drug used to ease blood p...
JAN 25, 2020
Cancer
JAN 25, 2020
Did you know these non-cancer drugs can also fight cancer?
A study from MIT. Harvard and the Dana-Farber Cancer Institute has concluded that almost 50 existing non-oncological drugs have anti-cancer properties capa...
JAN 25, 2020
Drug Discovery & Development
JAN 25, 2020
Drug Targets Gastrointestinal Cancer
The FDA has recently approved Ayvakit (avapritinib) for the treatment of unresectable and metastatic gastrointestinal stromal tumor (GIST) that occurs most...
Loading Comments...